Volume 10, Number 5—May 2004
Research
Enzyme-Linked Immunosorbent Assay and Serologic Responses to Pneumocystis jiroveci
Kieran R. Daly*
, Judy Koch*, Linda Levin*, and Peter D. Walzer*
, Judy Koch*, Linda Levin*, and Peter D. Walzer*
Table 2
Adjusted odds ratios (95% CI) measuring the associations between Western blot reactivity and ELISA values (25–75 percentile increase) among 189 study participantsa,b
| ELISA | Blood donor, n = 95 (95% CI) | PCP+, n = 33 (95% CI) | PCP–, n = 61 (95% CI) | HIV, n = 94 (95% CI) |
|---|---|---|---|---|
| 1 |
1.1 (0.9 to 1.4) |
5.1 (2.2 to 11.8) |
1.4 (0.8 to 2.6) |
2.7 (1.2 to 5.8) |
| 2 |
1.1 (0.9 to 1.4) |
20.4 (6.4 to 65.1) |
3.6 (2.0 to 6.6) |
8.6 (4.4 to 16.9) |
| 3 | 1.0 (0.9 to 1.1) | 11.6 (3.6 to 37.9) | 7.4 (3.6 to 15.1) | 9.3 (4.7 to 18.5) |
aCI, confidence interval; ELISA, enzyme-linked immunosorbent assay; PCP, Pneumocystis pneumonia.
bOdds ratios were obtained by using logistic regression. Positive associations were found between Western blot reactivity and increasing ELISA. Based on 95% confidence intervals, the odds of Western blot reactivity were significantly related (p < 0.05) to increasing ELISA 1, 2, and 3 among PCP+ patients and HIV patients across all antigens. For PCP– patients this result was true for ELISA 2 and 3 only. No significant results were found for the blood donor group.
Page created: February 22, 2011
Page updated: February 22, 2011
Page reviewed: February 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.